News

Hosted on MSN2mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has ... the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria. C3G is a progressive and ultra-rare kidney disease that is ...
Nasdaq2mon
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Novartis NVS obtains FDA ... disease. Approximately 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis. The approval Vanrafia marks the third ...
WebMD2mon
FDA Approves New Treatment for Serious Kidney Disorder
IgAN, which is also called Berger’s disease, is an autoimmune kidney condition where ... according to a news release by Novartis, the drug’s maker. The FDA’s decision is based on 36 ...
MedCity News2mon
Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels
An ultra-rare kidney disease that ... now has its first FDA-approved therapy. The affirmative regulatory decision is the third for Novartis’s Fabhalta, building up the drug’s pipeline-in ...
Reuters10mon
US FDA approves Novartis' kidney disease drug
Aug 7 (Reuters) - The U.S. Food and Drug Administration has approved the use of Novartis' (NOVN.S), opens new tab drug to reduce excess protein in the urine of patients with a type of kidney ...
Benzinga.com10mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
On Thursday, the FDA granted accelerated approval to Novartis AG’s NVS Fabhalta ... at risk of rapid disease progression. In December 2023, the FDA approved Fabhalta as the first oral ...
Benzinga.com2mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
This is the third US approval for Fabhalta and its second within the Novartis kidney disease portfolio since August 2024, when Fabhalta was granted accelerated approval by the FDA for the ...